Diagnosis and Management of Abdominal Lymphoma

Initial Clinical Assessment

• The National Comprehensive Cancer Network recommends evaluating for constitutional symptoms, including fever, night sweats, weight loss, alcohol intolerance, pruritus, and fatigue, as well as performing a thorough physical examination of all lymphoid regions, with special attention to the abdomen for hepatosplenomegaly and abdominal masses 1, 4
• Documenting performance status is crucial, as it impacts treatment decisions and prognosis, according to the National Comprehensive Cancer Network 1, 5

Laboratory Evaluation

• The National Comprehensive Cancer Network suggests complete blood count with differential to assess for cytopenias or abnormal cell populations, comprehensive metabolic panel including liver and renal function tests, and lactate dehydrogenase (LDH) and uric acid levels as markers of tumor burden and for prognostic purposes 1, 6
• Hepatitis B and C, HIV screening is mandatory before initiating rituximab therapy, as recommended by the National Comprehensive Cancer Network and Annals of Oncology 1, 2, 6

Imaging Studies

• The National Comprehensive Cancer Network recommends PET/CT scan (skull base to mid-thigh) as essential for initial staging of abdominal lymphoma, and diagnostic contrast-enhanced CT of neck, chest, abdomen, and pelvis if PET/CT is not immediately available 1, 4

Tissue Diagnosis

• Excisional lymph node biopsy is the preferred diagnostic method, according to the National Comprehensive Cancer Network, Annals of Oncology, and other guidelines 1, 2, 3
• Core needle biopsy should only be performed when excisional biopsy is not feasible, as stated by the National Comprehensive Cancer Network and Annals of Oncology 1, 2, 3

Bone Marrow Assessment

• Bone marrow biopsy is required for complete staging, according to the National Comprehensive Cancer Network, but may be omitted in certain circumstances, such as a negative PET scan or multifocal skeletal lesions 1, 6

Staging and Risk Assessment

• The Ann Arbor classification system is used for staging, as recommended by the National Comprehensive Cancer Network, Annals of Oncology, and other guidelines 1, 2, 3
• The International Prognostic Index (IPI) for diffuse large B-cell lymphoma, Follicular Lymphoma International Prognostic Index (FLIPI) for follicular lymphoma, and Mantle Cell Lymphoma International Prognostic Index (MIPI) for mantle cell lymphoma should be calculated based on lymphoma subtype, according to Annals of Oncology and other guidelines 2, 3, 5, 7